Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 99.6 EUR 0.91% Market Closed
Market Cap: 11.7B EUR
Have any thoughts about
Biomerieux SA?
Write Note

Biomerieux SA
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biomerieux SA
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Biomerieux SA
PAR:BIM
Net Issuance of Debt
-€5.4m
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edap Tms SA
NASDAQ:EDAP
Net Issuance of Debt
-€1.5m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
9%
Carmat SA
PAR:ALCAR
Net Issuance of Debt
-€697k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biosynex SA
PAR:ALBIO
Net Issuance of Debt
-€12m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Visiomed Group SA
PAR:ALVMG
Net Issuance of Debt
€1.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amplitude Surgical SA
PAR:AMPLI
Net Issuance of Debt
€567k
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biomerieux SA
Glance View

Market Cap
11.7B EUR
Industry
Health Care

Show Overview: BioMérieux SA: Pioneering Diagnostics for a Healthier World BioMérieux SA, a French multinational founded in 1963, stands at the forefront of the global diagnostics industry, driving innovation in infectious disease testing and food safety. With a mission to improve public health through advanced diagnostic solutions, the company has developed a robust portfolio of products that include molecular biology, microbiology, and immunoassays. Its cutting-edge technologies empower healthcare professionals to detect pathogens with speed and accuracy, making a direct impact on patient outcomes and aiding in the prevention of disease outbreaks. By continuously investing in research and development, BioMérieux not only maintains its competitive edge but also expands its reach in emerging markets, balancing its operations with a strong commitment to sustainability and social responsibility. As health crises grow more complex and interconnected, BioMérieux's efforts to enhance diagnostic capacity have never been more critical. The company's recent forays into automation and artificial intelligence signal a shift toward more integrated and efficient testing systems, equipping laboratories and healthcare providers worldwide with the tools necessary to meet rising healthcare demands. Investors can see the potential for substantial returns not only through BioMérieux's innovative product offerings but also through its strategic partnerships and global expansion initiatives. With a solid financial foundation and a vision anchored in improving patient care, BioMérieux represents a compelling opportunity for investors looking to align with a company dedicated to making a meaningful difference in the health of communities across the globe.

BIM Intrinsic Value
104.34 EUR
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Biomerieux SA's Net Issuance of Debt?
Net Issuance of Debt
-5.4m EUR

Based on the financial report for Jun 30, 2024, Biomerieux SA's Net Issuance of Debt amounts to -5.4m EUR.

What is Biomerieux SA's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
74%

Over the last year, the Net Issuance of Debt growth was 94%. The average annual Net Issuance of Debt growth rates for Biomerieux SA have been 74% over the past three years .

Back to Top